Alpha Tau Medical Ltd. (DRTS)
NASDAQ: DRTS · Real-Time Price · USD
2.460
-0.050 (-1.99%)
Apr 1, 2025, 3:45 PM EDT - Market open
Company Description
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, together with its subsidiaries, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States.
The company’s Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers.
Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.
Alpha Tau Medical Ltd.
| Country | Israel |
| Founded | 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 125 |
| CEO | Uzi Sofer |
Contact Details
Address: Kiryat Hamada Street 5 Jerusalem, 9777605 Israel | |
| Phone | 972 3 577 4115 |
| Website | alphatau.com |
Stock Details
| Ticker Symbol | DRTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001871321 |
| CUSIP Number | M0740A108 |
| ISIN Number | IL0011839383 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Uzi Sofer | Chief Executive Officer and Chairman |
| Raphi Levy | Chief Financial Officer |
| Amnon Gat | Chief Operations Officer |
| Ronen Segal | Chief Technology Officer |
| Dr. Robert B. Den M.D. | Chief Medical Officer and Member of Scientific Advisory Board |
| Prof. Yona Keisari | Chief Scientific Officer and Member of Scientific Advisory board |
| Rebecca Becker | Vice President of legal |
| Peter M. Melnyk | Chief Commercial Officer |
| Prof. Itzhak Kelson | Chief Physics Officer and Member of Scientific Advisory Board |
| Yael Zeiger | Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 12, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 12, 2025 | 6-K | Report of foreign issuer |
| Mar 12, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Feb 27, 2025 | 6-K | Report of foreign issuer |
| Feb 24, 2025 | 6-K | Report of foreign issuer |
| Feb 3, 2025 | 6-K | Report of foreign issuer |
| Jan 27, 2025 | 6-K | Report of foreign issuer |
| Dec 18, 2024 | 6-K | Report of foreign issuer |
| Dec 17, 2024 | 6-K | Report of foreign issuer |
| Dec 17, 2024 | 6-K | Report of foreign issuer |